ArticleBiology direct2026
Comprehensive analysis of the causal risk factor from hypertension associated with prognosis and therapeutic response in renal cell carcinoma by multi-omics analysis and validation.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is one of the known renal cell carcinoma (RCC)-associated factors. However, the gene expression patterns in hypertension tissues and the mechanisms of hypertension and RCC comorbidity have not been fully analyzed. This study aims to use single-cell RNA sequencing (scRNA-seq) integrated with multi-omics to explore RCC-associated hypertension gene modules and the causative relationship between key genes and the risk of RCC.
methodsHeterogenic expression programs in cross-species scRNA-seq tissues were classified by non-negative matrix factorization (NNMF) using scRNA-seq data from aortic tissues of hypertensive patients and spontaneously hypertensive rats (SHR). Molecular subtyping was performed using the bulk-seq and whole exome sequencing (WES) data of pan-cancer and RCC from TCGA. The Lasso-cox machine model was used to explore the predictors of survival and drug response in both TCGA, ICGC, E-MTAB-1980 and IMmotion 151 cohort. A total of 19 tissues were applied to perform scRNA-seq and then test the key gene expression. Finally, summary-data-based Mendelian Randomization (SMR) was used to verify the expression level of genes and traits of hypertension and RCC based on summary-level data from GWAS and expression quantitative trait loci (eQTL) studies. Two independent cohorts of European with GWAS summary statistics were used: hypertension cohort (119,731 cases and 343,202 controls) and RCC cohort (600 cases and 455,676 controls).
resultsscRNA-seq analysis revealed that the cross-species HTN-gene module consisted of 48 genes, which could classify the 523 patients into two subgroups with different survival and responses to targeted therapies. The results were then validated in three independent ccRCC cohorts. The core gene-panel scores were significantly different in vascular endothelial cells (P < 0.01), which also distinguished the cells from resistant and hypertensive tumor cells (both P < 0.001). SMR analysis demonstrated that TNXB was a reliable causative factor of hypertension and the RCC risk factor in hypertension (pSMR = 0.0029) and RCC (pSMR = 0.0031).
conclusionsThe results of the present study demonstrated that the HTN key genes were involved in the development of RCC and may represent potential therapeutic targets for the management of this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.